4HSG
Crystal structure of human PRMT3 in complex with an allosteric inhibitor (PRMT3- KTD)
Summary for 4HSG
Entry DOI | 10.2210/pdb4hsg/pdb |
Descriptor | PRMT3 protein, 1-(1,2,3-benzothiadiazol-6-yl)-3-(2-oxo-2-phenylethyl)urea, UNKNOWN ATOM OR ION, ... (4 entities in total) |
Functional Keywords | prmt3, allosteric inhibitor, structural genomics, structural genomics consortium, sgc, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 38594.26 |
Authors | Dobrovetsky, E.,Dong, A.,Liu, F.,Li, F.,Tempel, W.,Siarheyeva, A.,Hajian, T.,Smil, D.,Bountra, C.,Arrowsmith, C.H.,Edwards, A.M.,Brown, P.J.,Schapira, M.,Jin, J.,Vedadi, M.,Structural Genomics Consortium (SGC) (deposition date: 2012-10-30, release date: 2012-12-05, Last modification date: 2023-09-20) |
Primary citation | Liu, F.,Li, F.,Ma, A.,Dobrovetsky, E.,Dong, A.,Gao, C.,Korboukh, I.,Liu, J.,Smil, D.,Brown, P.J.,Frye, S.V.,Arrowsmith, C.H.,Schapira, M.,Vedadi, M.,Jin, J. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J. Med. Chem., 56:2110-2124, 2013 Cited by PubMed: 23445220DOI: 10.1021/jm3018332 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report